222. 一次性ネフローゼ症候群 Disease details / Clinical trials / Drug dev / DR info

100 MG AP1189
   SynAct Pharma Aps
      2020   Phase 2   NCT04456816   Denmark
Abatacept
   Bristol-Myers Squibb
      2016   Phase 2   NCT02592798   United States
   Bristol-Myers Squibb Company
      -   Phase 2   EUCTR2015-005450-36-Outside-EU/EEA   United States
Acei/ARB+ finerenone
   First Affiliated Hospital, Sun Yat-Sen University
      2024   Phase 4   NCT06573411   -
Acetaminophen
   Hoffmann-La Roche
      2021   Phase 3   NCT04629248   Argentina;Brazil;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
ACH-0144471
   Achillion Pharmaceuticals, Inc.
      2019   Phase 2   EUCTR2017-002674-39-NL   Australia;Belgium;Italy;Netherlands;United States
      2018   Phase 2   EUCTR2017-002674-39-BE   Australia;Belgium;Italy;Netherlands;United States
      2018   Phase 2   EUCTR2016-003525-42-NL   Australia;Belgium;Netherlands
      -   Phase 2   EUCTR2016-003525-42-BE   Australia;Belgium;Netherlands
   Alexion Pharmaceuticals
      2017   Phase 2   NCT03124368   Australia;Belgium;Netherlands
ACH-0144471 compresse
   ACHILLION PHARMACEUTICALS, INC.
      2018   Phase 2   EUCTR2017-002674-39-IT   Australia;Belgium;Italy;Netherlands;United States
ACH0144471 compresse
   ACHILLION PHARMACEUTICALS, INC.
      2018   Phase 2   EUCTR2017-002674-39-IT   Australia;Belgium;Italy;Netherlands;United States
ACT-HIB
   ACHILLION PHARMACEUTICALS, INC.
      2018   Phase 2   EUCTR2017-002674-39-IT   Australia;Belgium;Italy;Netherlands;United States
Acth
   Mayo Clinic
      2009   Phase 1   NCT00805753   Canada;United States
Acthar
   Icahn School of Medicine at Mount Sinai
      2018   Phase 4   NCT03025828   United States
   University of Colorado, Denver
      2019   Phase 3   NCT02683889   United States
   University of North Carolina, Chapel Hill
      2021   Phase 4   NCT02399462   United States
Acthar GEL
   Mallinckrodt ARD LLC
      2016   Phase 4   NCT02633046   Argentina;Australia;Canada;Chile;Hong Kong;Mexico;New Zealand;Peru;Puerto Rico;Turkey;United States
Adalimumab
   New York University School of Medicine
      2008   Phase 2   NCT00814255   Canada;United States
   North Shore Long Island Jewish Health System
      2005   Phase 1   NCT00193648   United States
   University of Michigan
      2019   Phase 2   NCT04009668   United States
Adoport
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2020-003233-38-IT   Argentina;Brazil;Canada;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
Adrenocorticotrophic hormone acth
   University Health Network, Toronto
      2010   Phase 1/Phase 2   NCT01093157   Canada
Advagraf 0,5MG
   Grupo Catalán de Estudio de enfermedades glomerulares. Sociedad Catalana de nefrología.
      2008   -   EUCTR2007-005410-39-ES   Spain
Advagraf 1MG
   Grupo Catalán de Estudio de enfermedades glomerulares. Sociedad Catalana de nefrología.
      2008   -   EUCTR2007-005410-39-ES   Spain
Advagraf 5MG
   Grupo Catalán de Estudio de enfermedades glomerulares. Sociedad Catalana de nefrología.
      2008   -   EUCTR2007-005410-39-ES   Spain
Aldosterone
   Assistance Publique - Hôpitaux de Paris
      2012   Phase 3   NCT01508468   France
   Chinese PLA General Hospital
      2023   Phase 4   NCT05839314   China
Aliskiren
   Columbia University
      2009   Phase 4   NCT01129557   United States
   Mayo Clinic
      2010   -   NCT01093781   United States
   Region Skane
      2020   Phase 2   NCT04183101   Sweden
Angiotensin
   Chinese PLA General Hospital
      2023   Phase 4   NCT05839314   China
Angiotensin II
   Assistance Publique - Hôpitaux de Paris
      2012   Phase 3   NCT01508468   France
AP1189
   SynAct Pharma ApS
      2021   Phase 2   EUCTR2020-000971-18-NO   Denmark;Norway
      2020   Phase 2   EUCTR2020-000971-18-DK   Denmark;Norway
Apixaban
   Aarhus University Hospital, Henrik Birn
      2020   Phase 1;Phase 2   EUCTR2019-001212-29-DK   Denmark
Apixaban 5 MG
   University of North Carolina, Chapel Hill
      2021   Phase 1   NCT04278729   United States
APL-2
   APELLIS PHARMACEUTCIALS, INC.
      2022   Phase 3   EUCTR2020-003767-25-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2020-002637-15-IT   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
   Apellis Pharmaceuticals, Inc.
      2022   Phase 3   EUCTR2020-003767-25-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003767-25-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003767-25-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003767-25-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003767-25-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003767-25-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003767-25-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
      2021   Phase 2   EUCTR2020-002637-15-NL   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2021   Phase 2   EUCTR2020-002637-15-FR   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2021   Phase 2   EUCTR2020-002637-15-AT   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2020   Phase 2   EUCTR2020-002637-15-GB   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2018   Phase 2   NCT03453619   United States
      -   Phase 3   EUCTR2022-002833-33-FR   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2022-002833-33-CZ   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2020-003767-25-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States
Aprovel 150 MG tablets
   Retrophin, Inc
      2015   Phase 2   EUCTR2014-002358-38-BE   Belgium;Czech Republic;Italy
      2014   Phase 2   EUCTR2014-002358-38-IT   Belgium;Czech Republic;Italy
   Travere Therapeutics, Inc.
      2015   Phase 2   EUCTR2014-002358-38-CZ   Belgium;Czech Republic;Czechia;Italy
Aspaveli
   Apellis Pharmaceuticals, Inc.
      2022   Phase 3   EUCTR2020-003767-25-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003767-25-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003767-25-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003767-25-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003767-25-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
      2021   Phase 2   EUCTR2020-002637-15-NL   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2021   Phase 2   EUCTR2020-002637-15-AT   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2022-002833-33-FR   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2022-002833-33-CZ   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;United Kingdom;United States
Atacicept
   Vera Therapeutics, Inc.
      2025   Phase 2   NCT06983028   -
ATG
   Alice Bertaina
      2023   Phase 1/Phase 2   NCT05508009   United States
Atrasentan
   CHINOOK THERAPEUTICS, U.S., Inc
      2021   Phase 2   EUCTR2020-004176-18-IT   Australia;Italy;Korea, Republic of;Spain;United Kingdom;United States
   Chinook Therapeutics U.S., Inc.
      2021   Phase 2   EUCTR2020-004176-18-ES   Australia;Korea, Republic of;Spain;United Kingdom;United States
   Novartis Pharmaceuticals
      2021   Phase 2   NCT04573920   Australia;Italy;Korea, Republic of;Spain;United Kingdom;United States
Avacopan
   ChemoCentryx, Inc.
      2018   Phase 2   EUCTR2017-001821-42-NL   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2018   Phase 2   EUCTR2017-001821-42-IT   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2018   Phase 2   EUCTR2017-001821-42-GB   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2018   Phase 2   EUCTR2017-001821-42-BE   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2017-001821-42-IE   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2017-001821-42-FR   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2017-001821-42-ES   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2017-001821-42-DK   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2017-001821-42-DE   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
B007
   Shanghai Jiaolian Drug Research and Development Co., Ltd
      2024   Phase 2/Phase 3   NCT06470191   China
      2023   Phase 1   NCT05668403   China
Bardoxolone methyl capsules
   Reata, a wholly owned subsidiary of Biogen
      2017   Phase 2   NCT03366337   United States
Basiliximab
   Astellas Pharma Global Development, Inc.
      2017   Phase 2   NCT02921789   Canada;United States
BCX9930
   BioCryst Pharmaceuticals
      2021   Phase 2   NCT05162066   France;Italy;Spain;United Kingdom
BCX9930 hydrochloride
   BIOCRYST PHARMACEUTICALS INC.
      2021   Phase 2   EUCTR2020-005855-19-IT   France;Germany;Hungary;Italy;Spain;United Kingdom
   BioCryst Pharmaceuticals Inc
      2022   Phase 2   EUCTR2020-005855-19-HU   France;Germany;Hungary;Italy;Romania;Spain;United Kingdom
      2021   Phase 2   EUCTR2020-005855-19-ES   France;Germany;Hungary;Italy;Spain;United Kingdom
Belimumab
   GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
      2012   -   EUCTR2011-000242-38-IT   Canada;Czech Republic;Germany;Italy;Spain;United Kingdom;United States
   GlaxoSmithKline Research & Development Ltd
      2013   -   EUCTR2011-000242-38-DE   Australia;Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2013   -   EUCTR2011-000242-38-CZ   Australia;Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2012   Phase 2   EUCTR2011-000242-38-GB   Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
   GlaxoSmithKline Research and Development Ltd
      2012   Phase 2   EUCTR2012-000385-38-GB   United Kingdom
   GlaxoSmithKline, S.A.
      2012   -   EUCTR2011-000242-38-ES   Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
   National Institute of Allergy and Infectious Diseases (NIAID)
      2020   Phase 2   NCT03949855   Canada;United States
   The Second Affiliated Hospital of Xi'an Jiaotong University
      2021   -   ChiCTR2100048518   China
Belimumab 10 MG
   GlaxoSmithKline
      2013   Phase 2   NCT01762852   Australia;Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
Benlysta
   GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
      2012   -   EUCTR2011-000242-38-IT   Canada;Czech Republic;Germany;Italy;Spain;United Kingdom;United States
   GlaxoSmithKline Research & Development Ltd
      2013   -   EUCTR2011-000242-38-DE   Australia;Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2013   -   EUCTR2011-000242-38-CZ   Australia;Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2012   Phase 2   EUCTR2011-000242-38-GB   Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
   GlaxoSmithKline Research and Development Ltd
      2012   Phase 2   EUCTR2012-000385-38-GB   United Kingdom
   GlaxoSmithKline, S.A.
      2012   -   EUCTR2011-000242-38-ES   Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
Bexsero
   ACHILLION PHARMACEUTICALS, INC.
      2018   Phase 2   EUCTR2017-002674-39-IT   Australia;Belgium;Italy;Netherlands;United States
Bexsero meningococcal group B vaccine FOR injection IN PRE-filled syringe
   APELLIS PHARMACEUTCIALS, INC.
      2022   Phase 3   EUCTR2020-003767-25-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States
BI 764198
   Boehringer Ingelheim
      2022   Phase 2   NCT05213624   Australia;Belgium;China;France;Germany;Ireland;Italy;New Zealand;Spain;United Kingdom;United States
   Boehringer Ingelheim España S.A.
      2022   Phase 2   EUCTR2020-000384-23-ES   Australia;Belgium;France;Germany;Hungary;Ireland;Italy;Spain;United Kingdom;United States
   Boehringer Ingelheim International GmbH
      2022   Phase 2   EUCTR2020-000384-23-IE   Australia;Belgium;China;France;Germany;Ireland;Italy;New Zealand;Spain;United Kingdom;United States
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2022   Phase 2   EUCTR2020-000384-23-DE   Australia;Belgium;China;France;Germany;Hungary;Ireland;Italy;Spain;United Kingdom;United States
   Boehringer Ingelheim SComm
      2022   Phase 2   EUCTR2020-000384-23-BE   Australia;Belgium;China;France;Germany;Ireland;Italy;New Zealand;Spain;United Kingdom;United States
   Boehringer-Ingelheim France
      2022   Phase 2   EUCTR2020-000384-23-FR   Australia;Belgium;France;Germany;Hungary;Ireland;Italy;Spain;United Kingdom;United States
Bleselumab
   Astellas Pharma Global Development, Inc.
      2017   Phase 2   NCT02921789   Canada;United States
BMS-188667
   Bristol-Myers Squibb Company
      -   Phase 2   EUCTR2015-005450-36-Outside-EU/EEA   United States
Bortezomib
   Ruijin Hospital
      2022   -   NCT05383547   China
Butyric acid
   Shanghai Children's Hospital
      2022   Phase 0   ChiCTR2200057174   China
Calcium
   Assistance Publique - Hôpitaux de Paris
      2012   Phase 3   NCT01508468   France
CCX140-B
   Amgen
      2018   Phase 2   NCT03536754   Australia;Canada;France;Italy;New Zealand;Poland;United Kingdom;United States
   CHEMOCENTRYX, INC.
      2018   Phase 2   EUCTR2017-003021-15-IT   Australia;Canada;Czechia;France;Germany;Italy;New Zealand;Poland;United Kingdom;United States
   ChemoCentryx
      2018   Phase 2   NCT03703908   United States
   ChemoCentryx, Inc.
      2019   Phase 2   EUCTR2017-003022-32-PL   Canada;France;Poland;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003021-15-PL   Australia;Canada;Czech Republic;France;Germany;Italy;New Zealand;Poland;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003021-15-GB   Australia;Canada;Czech Republic;France;Germany;Italy;New Zealand;Poland;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003021-15-FR   Australia;Canada;Czech Republic;France;Germany;Italy;New Zealand;Poland;United Kingdom;United States
CCX168
   ChemoCentryx, Inc.
      2018   Phase 2   EUCTR2017-001821-42-NL   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2018   Phase 2   EUCTR2017-001821-42-IT   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2018   Phase 2   EUCTR2017-001821-42-GB   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2018   Phase 2   EUCTR2017-001821-42-BE   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2017-001821-42-IE   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2017-001821-42-FR   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2017-001821-42-ES   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2017-001821-42-DK   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2017-001821-42-DE   Belgium;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Spain;United Kingdom;United States
CDX-1135
   Celldex Therapeutics
      2013   Phase 1   NCT01791686   United States
Cholesterol
   Yuebei People’s Hospital
      2022   Phase 0   ChiCTR2200058162   China
Ciclofosfamida
   Grupo Catalán de Estudio de enfermedades glomerulares. Sociedad Catalana de nefrología.
      2008   -   EUCTR2007-005410-39-ES   Spain
Ciclosporin
   Division of Kidney and Dialysis, Department of Internal Medicine,Hyogo College of Medicine
      2007   Phase 4   JPRN-UMIN000001099   Japan
Ciclosporin soft capsules
   Chinese PLA General Hospital
      2023   Phase 4   NCT05839314   China
Clinimacs® TCR A/ß reagent KIT and clinimacs® CD19 system
   Alice Bertaina
      2023   Phase 1/Phase 2   NCT05508009   United States
Conventional therapy
   China-Japan Friendship Hospital
      2021   Phase 4   ChiCTR2100050967   China
   Shanghai Children's Hospital
      2022   Phase 0   ChiCTR2200057174   China
   Zhujiang Hospital
      2016   Phase 2   NCT02966717   China
Corticosteroid
   National Taiwan University Hospital
      2006   Phase 3   NCT00354731   Taiwan
   Shengjing Hospital of China Medical University
      2020   Phase 4   ChiCTR2300076346   China
Creatinine
   Yuebei People’s Hospital
      2022   Phase 0   ChiCTR2200058162   China
CSA
   Beijing Hospital of TCM, Capital Medical University
      2023   Phase 2-3   ChiCTR2300067939   China
   Department of Nephrology, China-Japan Friendship Hospital
      2014   -   ChiCTR-IPR-14005366   -
   Ruijin Hospital, affiliated to Shanghai Jiaotong University, School of medicine
      2016   Phase 4   ChiCTR-IPR-16008527   China
CXA-10
   Complexa, Inc.
      2018   Phase 2   NCT03422510   United States
Cyclophosphamide
   Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
      2012   Phase 3   NCT03018535   Italy
   Baoji Central Hospital
      2016   -   ChiCTR-IPR-16008344   China
   Department of Nephrology, China-Japan Friendship Hospital
      2014   -   ChiCTR-IPR-14005366   -
   Department of Nephrology, The First Affiliated Hospital of Zhejiang Chinese Medical University
      2019   -   ChiCTR1800019833   China
   Fundacion Renal Iñigo Alvarez Toledo
      2015   -   EUCTR2013-000226-55-NL   Netherlands;Spain
   Hospital Universitario 12 de Octubre
      2014   Phase 3   NCT01955187   Spain
   Huashan Hospital
      2024   Phase 3   NCT06781944   China
   Nanjing University School of Medicine
      2011   -   NCT01451489   China
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2000   Phase 1/Phase 2   NCT00007475   United States
   Peking Union Medical College Hospital
      2021   Phase 3   NCT04745728   China
   Peking University Third Hospital
      2022   -   ChiCTR2200057381   China
   People’s Hospital of Guangxi Zhuang Autonomous Region
      2022   -   ChiCTR2200059658   China
   Renmin Hospital of Wuhan University
      2024   Phase 2   NCT06614985   China
   Ruijin Hospital, affiliated to Shanghai Jiaotong University, School of medicine
      2016   Phase 4   ChiCTR-IPR-16008527   China
   Shanghai Dongfang Hospital
      2021   Phase 0   ChiCTR2100049205   China
   Sichuan Provincial People's Hospital
      2018   -   ChiCTR1800016140   China
   The First Affiliated Hospital of Bengbu Medical College
      2020   Phase 4   ChiCTR2000033766   China
   The First Affiliated Hospital of Shandong First Medical University&Shandong Provincial Qianfoshan Hospital
      2021   -   ChiCTR2100050205   China
   The Second Affiliated Hospital of Xi'an Jiaotong University
      2021   -   ChiCTR2100048518   China
   Tianjin First Central Hospital
      2017   -   ChiCTR-IPR-17011702   China
Cyclophosphamide 100 MG/KG
   Alice Bertaina
      2023   Phase 1/Phase 2   NCT05508009   United States
Cyclophosphamide 1200 MG/KG
   Alice Bertaina
      2023   Phase 1/Phase 2   NCT05508009   United States
Cyclophosphamide and steroids
   Radboud University
      1997   Phase 3   NCT00135954   Netherlands
Cyclosporin
   Assiut University
      2017   Phase 3   NCT03180723   -
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2004   Phase 3   NCT00135811   United States
   Sun Yat-sen University
      2014   Phase 2   NCT02173106   China
Cyclosporin capsules
   Shanghai Jiaolian Drug Research and Development Co., Ltd
      2024   Phase 2/Phase 3   NCT06470191   China
Cyclosporin, LOW dose steroid
   Kyungpook National University
      2011   Phase 3   NCT01282073   Korea, Republic of
Cyclosporine
   Beijing Hospital of TCM, Capital Medical University
      2023   Phase 2-3   ChiCTR2300067939   China
   Beijing Mabworks Biotech Co., Ltd.
      2023   Phase 3   NCT05862233   China
      2022   Phase 1/Phase 2   NCT05398653   China
   BioRay Pharmaceutical Co., Ltd.
      2024   Phase 2   NCT06642909   China
   First teaching hospital of Tianjin university of traditional chinese medicine
      2020   Phase 0   ChiCTR2200065012   China
   Mayo Clinic
      2011   Phase 2/Phase 3   NCT01180036   Canada;United States
   Nephrology Division, First Hospital Affiliated to Army Medical University
      2019   Phase 4   ChiCTR1900021757   China
   Peking Union Medical College Hospital
      2021   Phase 3   NCT04743739   China
   People’s Hospital of Guangxi Zhuang Autonomous Region
      2022   -   ChiCTR2200059658   China
   Renal Division, Peking University First Hospital
      2017   -   ChiCTR-INR-17012212   China
   Yokohama city university graduate school of medicine
      2005   -   JPRN-UMIN000004653   Japan
   Yoshihiko Saito
      2007   -   JPRN-UMIN000000963   Japan
   Zhongshan Hospital, Fudan University
      2024   Phase 2   ChiCTR2400091563   China
Cyclosporins
   Guangdong Provincial People's Hospital
      2018   Phase 4   NCT03170323   China
D-galactose
   Children's Research Institute
      2009   -   NCT01113385   United States
D5W
   Bristol-Myers Squibb
      2016   Phase 2   NCT02592798   United States
DacortíN 2,5MG
   Grupo Catalán de Estudio de enfermedades glomerulares. Sociedad Catalana de nefrología.
      2008   -   EUCTR2007-005410-39-ES   Spain
DacortíN 30MG
   Grupo Catalán de Estudio de enfermedades glomerulares. Sociedad Catalana de nefrología.
      2008   -   EUCTR2007-005410-39-ES   Spain
DacortíN 5MG
   Grupo Catalán de Estudio de enfermedades glomerulares. Sociedad Catalana de nefrología.
      2008   -   EUCTR2007-005410-39-ES   Spain
Dalteparin
   Aarhus University Hospital, Henrik Birn
      2020   Phase 1;Phase 2   EUCTR2019-001212-29-DK   Denmark
Dandshen
   First Affiliated Hospital of Wenzhou Medical University
      2012   -   NCT06071533   China
Danicopan
   Alexion
      2018   Phase 2   NCT03459443   Australia;Belgium;Italy;Netherlands;United States
Danzhu fuyuan granule
   Jingqing Hu
      2020   -   NCT04498962   China
Dapagliflozin
   The First Affiliated Hospital of the People's Liberation Army Air Force University of Military Medicine
      2024   -   ChiCTR2400086359   China
   University Health Network, Toronto
      2015   Phase 4   NCT02585804   Canada
Dexamethasone
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2000   Phase 2   NCT00004990   United States
Diphenhydramine
   Hoffmann-La Roche
      2021   Phase 3   NCT04629248   Argentina;Brazil;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
DMX-200
   Dimerix Bioscience Pty Ltd
      2022   Phase 3   NCT05183646   Argentina;Australia;Brazil;Denmark;France;Hong Kong;New Zealand;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-004174-64-FR   Argentina;Australia;Brazil;Denmark;France;Hong Kong;Korea, Republic of;New Zealand;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-004174-64-ES   Argentina;Australia;Brazil;Denmark;France;Hong Kong;Korea, Republic of;New Zealand;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-004174-64-DK   Argentina;Australia;Brazil;Denmark;France;Hong Kong;New Zealand;Spain;Taiwan;United Kingdom;United States
Eculizumab
   Columbia University
      2010   Phase 1   NCT01221181   United States
   IRCCS- Mario Negri Institute
      2014   Phase 2   EUCTR2013-003826-10-IT   Italy
   Mario Negri Institute for Pharmacological Research
      2014   Phase 2   NCT02093533   Italy
Efgartigimod IV
   argenx
      2023   Phase 2   NCT05810961   China
Eliquis
   Aarhus University Hospital, Henrik Birn
      2020   Phase 1;Phase 2   EUCTR2019-001212-29-DK   Denmark
Enalapril
   Region Skane
      2020   Phase 2   NCT04183101   Sweden
Endoxan baxter*50CPR RIV 50MG
   AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
      2012   -   EUCTR2011-006115-59-IT   Italy
EVER001
   Everest Medicines (China) Co.,Ltd.
      2023   Phase 1   NCT05800873   China
Evolocumab
   Department of Nephrology, Nippon Medical School
      2019   -   JPRN-UMIN000038242   Japan
   Department of Nephrology, Shandong Provincial Hospital affiliated to Shandong First Medical University
      2023   Phase 0   ChiCTR2300072268   China
FCM
   Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
      2020   Phase 0   ChiCTR2000037467   China
Felzartamab
   Biogen
      2025   Phase 3   NCT06962800   United States
   MorphoSys AG
      2021   Phase 1;Phase 2   EUCTR2019-000780-24-PL   Australia;Belgium;European Union;France;Italy;Korea, Republic of;Netherlands;Poland;Spain;United States
FG-3019
   FibroGen
      2008   Phase 1   NCT00782561   United States
Filgotinib
   Gilead Sciences
      2017   Phase 2   NCT03285711   United States
Finerenone
   The First Affiliated Hospital of the People's Liberation Army Air Force University of Military Medicine
      2024   -   ChiCTR2400086359   China
FK506
   Nanjing University School of Medicine
      2011   -   NCT01451489   China
   Shanghai Jiaotong University Affiliated Ruijin Hospital
      2008   -   ChiCTR-TRC-10001024   China
   The Seventh Affiliated Hospital of Sun Yat sen University
      2023   Phase 4   ChiCTR2200067000   China
   Zhi-Hong Liu, M.D.
      2010   -   NCT01161459   China
FKC288
   Nanjing University School of Medicine
      2024   Phase 1   NCT06285279   China
Fludarabine
   Alice Bertaina
      2023   Phase 1/Phase 2   NCT05508009   United States
Fluvastatin
   Treatment center of kidney disease, 281th hospital of PLA
      2009   Phase 1 study   ChiCTR-TQR-12002602   China
Fragmin
   Aarhus University Hospital, Henrik Birn
      2020   Phase 1;Phase 2   EUCTR2019-001212-29-DK   Denmark
Fresolimumab
   Genzyme Corporation
      2013   -   EUCTR2012-002365-35-IT   Brazil;France;Germany;Italy;Spain;United States
      2013   -   EUCTR2012-002365-35-ES   Brazil;France;Germany;Italy;Spain;United States
      2013   -   EUCTR2012-002365-35-DE   Brazil;France;Germany;Italy;Spain;United States
   Genzyme, a Sanofi Company
      2012   Phase 2   NCT01665391   Brazil;Germany;Italy;Spain;United States
Frexalimab
   Sanofi
      2024   Phase 2   NCT06500702   Argentina;Australia;Brazil;Canada;Chile;China;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Galactose
   New York University School of Medicine
      2008   Phase 2   NCT00814255   Canada;United States
   North Shore Long Island Jewish Health System
      2008   Phase 1   NCT00816504   United States
      2008   Phase 1   NCT00816478   United States
Gazyvaro
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2020-003233-38-IT   Argentina;Brazil;Canada;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
   F.Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-003233-38-PL   Argentina;Brazil;Canada;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
      2021   Phase 3   EUCTR2020-003233-38-FR   Argentina;Brazil;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
Gazyvaro - 1000 MG - concentrato PER soluzione PER infusione - USO endovenoso - flaconcino - 1000MG/40ML - 1 flaconcino
   IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
      2021   Phase 2   EUCTR2021-004864-81-IT   Italy
GC1008
   Genzyme Corporation
      2013   -   EUCTR2012-002365-35-IT   Brazil;France;Germany;Italy;Spain;United States
      2013   -   EUCTR2012-002365-35-ES   Brazil;France;Germany;Italy;Spain;United States
      2013   -   EUCTR2012-002365-35-DE   Brazil;France;Germany;Italy;Spain;United States
   Genzyme, a Sanofi Company
      2007   Phase 1   NCT00464321   Germany;Italy;United Kingdom;United States
Genoxal
   Grupo Catalán de Estudio de enfermedades glomerulares. Sociedad Catalana de nefrología.
      2008   -   EUCTR2007-005410-39-ES   Spain
GFB-887
   Goldfinch Bio, Inc.
      2020   Phase 2   NCT04387448   United States
Glucocorticoid + cytoxan
   Qianfoshan Hospital
      2023   -   NCT05667883   -
Glucocorticoid + tacrolimus
   Qianfoshan Hospital
      2023   -   NCT05667896   -
Glucocorticoid combined with cyclophosphamide induction + maintenance
   RenJi Hospital
      2022   -   NCT05532111   -
   Renji Hospital Affiliated to Shanghai jiao tong university school of medicine
      2022   -   ChiCTR2200063389   China
Glucocorticoids
   Huashan Hospital
      2024   Phase 3   NCT06781944   China
   Shanghai Dongfang Hospital
      2021   Phase 0   ChiCTR2100049205   China
Glutamine
   Shanghai Children's Hospital
      2022   Phase 0   ChiCTR2200057174   China
GSK1550188
   GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
      2012   -   EUCTR2011-000242-38-IT   Canada;Czech Republic;Germany;Italy;Spain;United Kingdom;United States
   GlaxoSmithKline Research & Development Ltd
      2013   -   EUCTR2011-000242-38-DE   Australia;Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2013   -   EUCTR2011-000242-38-CZ   Australia;Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2012   Phase 2   EUCTR2011-000242-38-GB   Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
   GlaxoSmithKline Research and Development Ltd
      2012   Phase 2   EUCTR2012-000385-38-GB   United Kingdom
   GlaxoSmithKline, S.A.
      2012   -   EUCTR2011-000242-38-ES   Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
GZ402669
   Genzyme Corporation
      2013   -   EUCTR2012-002365-35-IT   Brazil;France;Germany;Italy;Spain;United States
      2013   -   EUCTR2012-002365-35-ES   Brazil;France;Germany;Italy;Spain;United States
      2013   -   EUCTR2012-002365-35-DE   Brazil;France;Germany;Italy;Spain;United States
H.P. acthar GEL
   Stanford University
      2009   Phase 4   NCT01155141   United States
HS-10390 tablet
   Hansoh BioMedical R&D Company
      2023   Phase 1   NCT05942625   China
Huaier granule
   Chinese PLA General Hospital
      2023   Phase 4   NCT05839314   China
Huaiqihuang granule
   Jianhua Zhou
      2023   Phase 4   NCT05772871   China
Hydroxychloroquine
   Nephrology Division, First Hospital Affiliated to Army Medical University
      2019   Phase 4   ChiCTR1900021757   China
   Renal Division, Peking University First Hospital
      2016   -   ChiCTR2100045947   China
   Shengjing Hospital of China Medical University
      2020   Phase 4   ChiCTR2300076346   China
   The First Affiliated Hospital of the People's Liberation Army Air Force University of Military Medicine
      2024   -   ChiCTR2400086359   China
   The Seventh Affiliated Hospital of Sun Yat sen University
      2023   Phase 4   ChiCTR2200067000   China
INN NOT available YET
   ChemoCentryx, Inc.
      2018   Phase 2   EUCTR2017-003021-15-PL   Australia;Canada;Czech Republic;France;Germany;Italy;New Zealand;Poland;United Kingdom;United States
Intravenous (I.V.) methylprednisolone 1000 MG, total 9
   Radboud University
      2002   Phase 2/Phase 3   NCT00135967   Netherlands
Intravenous injection
   Royan Institute
      2015   Phase 1   NCT02382874   Iran, Islamic Republic of
   Shanghai Children’s Hospital
      2025   Phase 0   ChiCTR2500101933   China
   Zhongshan Hospital, Fudan University
      2024   Phase 2   ChiCTR2400091563   China
Ioexolo
   IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
      2021   Phase 2   EUCTR2021-004864-81-IT   Italy
Iptacopan
   Hirano Takamitsu
      2023   Phase 3   JPRN-jRCT2031230365   Canada;Japan;Turkey;US;Vietnam
   Maruyama Hideki
      2022   Phase 3   JPRN-jRCT2041220097   Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;UK;US
   Novartis Pharma AG
      2023   Phase 3   EUCTR2018-004253-24-CZ   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Spain;Switzerland;Türkiye;United Kingdom;United States
      2020   Phase 2   EUCTR2019-001734-34-NL   Argentina;China;Czechia;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2019-001734-34-DE   Argentina;China;Czech Republic;Czechia;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States
      -   Phase 3   EUCTR2018-004253-24-DE   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Spain;Switzerland;Türkiye;United Kingdom;United States
   Novartis Pharmaceuticals
      2023   Phase 3   NCT05755386   Argentina;Brazil;Canada;Czechia;France;Germany;India;Israel;Italy;Japan;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;Vietnam
Iptacopan hydrochloride
   Novartis Pharma AG
      2023   Phase 3   EUCTR2018-004253-24-NL   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Spain;Switzerland;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2018-004253-24-GR   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Spain;Switzerland;Türkiye;United Kingdom;United States
Irbesartan
   Retrophin, Inc
      2015   Phase 2   EUCTR2014-002358-38-BE   Belgium;Czech Republic;Italy
      2014   Phase 2   EUCTR2014-002358-38-IT   Belgium;Czech Republic;Italy
   Travere Therapeutics, Inc.
      2018   Phase 3   NCT03493685   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
      2015   Phase 2   EUCTR2014-002358-38-CZ   Belgium;Czech Republic;Czechia;Italy
      2014   Phase 2   NCT01613118   Belgium;Czech Republic;Czechia;Italy;United States
Irbesartan tablets
   RETROPHIN, INC
      2018   Phase 3   EUCTR2016-005141-23-IT   Australia;Belgium;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Korea, Republic of;New Zealand;Poland;Portugal;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
   Retrophin, Inc.
      2018   Phase 3   EUCTR2016-005141-23-GB   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2016-005141-23-FR   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Italy;Korea, Republic of;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
Irbesartan tablets (approved IN THE USA. reference listed drug avapro) NDC # 43547-0374-03
   Retrophin, Inc.
      2018   Phase 3   EUCTR2016-005141-23-HU   Australia;Belgium;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Italy;Korea, Republic of;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2016-005141-23-ES   Australia;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Korea, Republic of;Poland;South Africa;Spain;Taiwan;United Kingdom;United States
Irbesartan tablets (NDC# 31722-729-30 approved IN THE united states)
   Travere Therapeutics Inc.
      2019   Phase 3   EUCTR2016-005141-23-DE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
IXP
   Vertex Pharmaceuticals Incorporated
      2024   Phase 1   NCT06529796   United States
Jianpixiaozhong particles and wuse dietotherapy
   Shanghai University of Traditional Chinese Medicine
      2015   -   NCT02610595   China
Kidney transplant
   Alice Bertaina
      2023   Phase 1/Phase 2   NCT05508009   United States
Lanraplenib
   Gilead Sciences
      2017   Phase 2   NCT03285711   United States
Lansoprazole, amoxicillin, clarithromycin
   Istanbul University
      2006   -   NCT00983034   Turkey
Levamisole
   Jianhua Zhou
      2023   Phase 4   NCT05772871   China
Lisinopril, losartan, and atorvastatin
   New York University School of Medicine
      2008   Phase 2   NCT00814255   Canada;United States
LNP023
   Maruyama Hideki
      2022   Phase 3   JPRN-jRCT2041220097   Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;UK;US
   Novartis Pharmaceuticals
      2019   Phase 2   NCT04154787   Argentina;China;Czechia;France;Germany;India;Netherlands;Singapore;Spain;Taiwan;United Kingdom;United States
      2019   Phase 3   NCT03955445   Argentina;Brazil;Canada;China;Czechia;France;Germany;Greece;Israel;Italy;Japan;Netherlands;Spain;Switzerland;Turkey;United Kingdom;United States
LNP023 hydrochloride salt
   Novartis Farmacéutica, S.A.
      2019   Phase 2   EUCTR2019-001734-34-ES   Argentina;Czech Republic;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;United Kingdom;United States
   Novartis Pharma AG
      2023   Phase 3   EUCTR2018-004253-24-NL   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Spain;Switzerland;Türkiye;United Kingdom;United States
      2023   Phase 3   EUCTR2018-004253-24-CZ   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Spain;Switzerland;Türkiye;United Kingdom;United States
      2022   Phase 3   EUCTR2018-004253-24-GR   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Spain;Switzerland;Türkiye;United Kingdom;United States
      2020   Phase 2   EUCTR2019-001734-34-NL   Argentina;China;Czechia;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2019-001734-34-GB   Argentina;Czech Republic;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2019-001734-34-FR   Argentina;Czech Republic;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2019-001734-34-DE   Argentina;China;Czech Republic;Czechia;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States
      -   Phase 3   EUCTR2018-004253-24-DE   Argentina;Belgium;Brazil;Canada;China;Czech Republic;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Spain;Switzerland;Türkiye;United Kingdom;United States
Losartan
   Shanghai University of T.C.M
      2014   -   ChiCTR-TRC-14005064   China
Losartan tablets & qingremoshen granule
   wanglin
      2011   -   NCT01845688   China
Losmapimod
   GlaxoSmithKline
      2014   Phase 2   NCT02000440   Canada;United States
Mabthera
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
      2019   Phase 2   EUCTR2018-003437-15-FR   France
   Fundacion Renal Iñigo Alvarez Toledo
      2015   -   EUCTR2013-000226-55-NL   Netherlands;Spain
   IST. DI RICERCHE FARMACOLOG. M. NEGRI
      2009   Phase 3   EUCTR2008-006750-17-IT   Italy
Mabthera 100 MG concentrate FOR solution FOR infusion
   Novartis Pharma AG
      2020   Phase 2   EUCTR2019-001734-34-NL   Argentina;China;Czechia;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2019-001734-34-GB   Argentina;Czech Republic;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2019-001734-34-FR   Argentina;Czech Republic;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2019-001734-34-DE   Argentina;China;Czech Republic;Czechia;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States
Mabthera 500 MG concentrate FOR solution FOR infusion
   Novartis Pharma AG
      2020   Phase 2   EUCTR2019-001734-34-NL   Argentina;China;Czechia;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2019-001734-34-GB   Argentina;Czech Republic;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2019-001734-34-DE   Argentina;China;Czech Republic;Czechia;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States
Mabthera*EV 1FL 50ML 500MG
   AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
      2012   -   EUCTR2011-006115-59-IT   Italy
Mannac
   National Human Genome Research Institute (NHGRI)
      2025   Phase 2   NCT06664814   United States
Medrol
   Hopital Erasme
      2006   Phase 4   EUCTR2005-004460-22-BE   Belgium
Medrol*10CPR DIV 4MG
   AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
      2012   -   EUCTR2011-006115-59-IT   Italy
Melphalan
   Alice Bertaina
      2023   Phase 1/Phase 2   NCT05508009   United States
Menveo
   ACHILLION PHARMACEUTICALS, INC.
      2018   Phase 2   EUCTR2017-002674-39-IT   Australia;Belgium;Italy;Netherlands;United States
Mesenchymal stem cells
   Zhujiang Hospital
      2016   Phase 2   NCT02966717   China
Metformin + standard OF care
   Yale University
      2023   Phase 1/Phase 2   NCT06090227   United States
Methylprednisolone
   Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
      2012   Phase 3   NCT03018535   Italy
   Fundacion Renal Iñigo Alvarez Toledo
      2015   -   EUCTR2013-000226-55-NL   Netherlands;Spain
   Hoffmann-La Roche
      2021   Phase 3   NCT04629248   Argentina;Brazil;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
   Hospital Universitario 12 de Octubre
      2014   Phase 3   NCT01955187   Spain
   The First Affiliated Hospital of Dalian Medical University
      2009   -   ChiCTR-ONC-12002809   China
   Tianjin Hospital
      2004   Phase 0   ChiCTR1900022518   China
Methylprednisone
   Astellas Pharma Global Development, Inc.
      2017   Phase 2   NCT02921789   Canada;United States
MIL62
   Beijing Mabworks Biotech Co., Ltd.
      2023   Phase 3   NCT05862233   China
      2022   Phase 1/Phase 2   NCT05398653   China
Mizoribine
   Japanese Study Group of Renal Disease in Children(JSRDC)
      2006   -   JPRN-C000000158   Japan
      2001   -   JPRN-C000000379   Japan
   Project team for treatment of refractory nephrotic syndrome
      2004   -   JPRN-C000000368   Japan
   The study group of treatment for aged patients with nephrotic syndrome.
      2012   -   JPRN-UMIN000008919   Japan
   Tianjin First Central Hospital
      2017   -   ChiCTR-IPR-17011702   China
MMF
   Astellas Pharma Global Development, Inc.
      2017   Phase 2   NCT02921789   Canada;United States
MMF and dexamethasone
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2004   Phase 3   NCT00135811   United States
Modified ponticelli regimen
   Beijing Friendship Hospital
      2022   -   NCT05782933   China
MOR03087
   Human Immunology Biosciences, Inc.
      2020   Phase 2   EUCTR2020-002985-15-GR   Georgia;Germany;Greece;Korea, Republic of;Russian Federation;United Kingdom
   MorphoSys AG
      2021   Phase 1;Phase 2   EUCTR2019-000780-24-PL   Australia;Belgium;European Union;France;Italy;Korea, Republic of;Netherlands;Poland;Spain;United States
      2020   Phase 2   EUCTR2020-002985-15-GB   Australia;Georgia;Germany;Greece;Korea, Republic of;Russian Federation;Taiwan;United Kingdom
      2020   Phase 2   EUCTR2020-002985-15-DE   France;Georgia;Germany;Greece;Hong Kong;Korea, Republic of;Russian Federation;Taiwan;United Kingdom
      2019   Phase 1;Phase 2   EUCTR2019-000780-24-NL   Australia;European Union;France;Italy;Korea, Republic of;Netherlands;Poland;Spain;United States
      2019   Phase 1;Phase 2   EUCTR2019-000780-24-IT   Belgium;European Union;France;Italy;Netherlands;Poland;Spain;United States
      2019   Phase 1;Phase 2   EUCTR2019-000780-24-FR   Belgium;European Union;France;Italy;Netherlands;Poland;Spain;United States
      2019   Phase 1;Phase 2   EUCTR2019-000780-24-ES   Belgium;European Union;France;Italy;Netherlands;Poland;Spain;United States
MOR202
   HI-Bio, A Biogen Company
      2021   Phase 2   NCT04733040   Georgia;Germany;Greece;Korea, Republic of;Russian Federation;Taiwan;United Kingdom
      2019   Phase 1/Phase 2   NCT04145440   Australia;Belgium;France;Italy;Korea, Republic of;Netherlands;Poland;Spain;United States
   Human Immunology Biosciences, Inc.
      2020   Phase 2   EUCTR2020-002985-15-GR   Georgia;Germany;Greece;Korea, Republic of;Russian Federation;United Kingdom
   IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
      2021   Phase 2   EUCTR2021-000835-30-IT   Italy
   Mario Negri Institute for Pharmacological Research
      2021   Phase 2   NCT04893096   Italy
   MorphoSys AG
      2021   Phase 1;Phase 2   EUCTR2019-000780-24-PL   Australia;Belgium;European Union;France;Italy;Korea, Republic of;Netherlands;Poland;Spain;United States
      2020   Phase 2   EUCTR2020-002985-15-GB   Australia;Georgia;Germany;Greece;Korea, Republic of;Russian Federation;Taiwan;United Kingdom
      2020   Phase 2   EUCTR2020-002985-15-DE   France;Georgia;Germany;Greece;Hong Kong;Korea, Republic of;Russian Federation;Taiwan;United Kingdom
      2019   Phase 1;Phase 2   EUCTR2019-000780-24-NL   Australia;European Union;France;Italy;Korea, Republic of;Netherlands;Poland;Spain;United States
      2019   Phase 1;Phase 2   EUCTR2019-000780-24-IT   Belgium;European Union;France;Italy;Netherlands;Poland;Spain;United States
      2019   Phase 1;Phase 2   EUCTR2019-000780-24-FR   Belgium;European Union;France;Italy;Netherlands;Poland;Spain;United States
      2019   Phase 1;Phase 2   EUCTR2019-000780-24-ES   Belgium;European Union;France;Italy;Netherlands;Poland;Spain;United States
MP and CTX
   Wenhu Liu
      2018   -   NCT03466801   China
Mycophenolate mofetil
   Astellas Pharma Global Development, Inc.
      2017   Phase 2   NCT02921789   Canada;United States
   Guangdong Provincial People's Hospital
      2018   Phase 4   NCT03170323   China
   Radboud University
      2002   Phase 2/Phase 3   NCT00135967   Netherlands
   The First Affiliated Hospital of Shandong First Medical University&Shandong Provincial Qianfoshan Hospital
      2021   -   ChiCTR2100050205   China
Mycophenolate mofetil, LOW dose steroid
   Kyungpook National University
      2011   Phase 3   NCT01282073   Korea, Republic of
Mycophenolate sodium
   UHB NHS Foundation Trust
      2010   Phase 2   EUCTR2009-016003-26-GB   United Kingdom
Mycophenolic acid
   UHB NHS Foundation Trust
      2010   Phase 2   EUCTR2009-016003-26-GB   United Kingdom
Mycophenolic sodium
   UHB NHS Foundation Trust
      2010   Phase 2   EUCTR2009-016003-26-GB   United Kingdom
Myfortic
   Assistance Publique - Hôpitaux de Paris
      2009   Phase 3   NCT01197040   France
Myfortic 180MG tablets
   UHB NHS Foundation Trust
      2010   Phase 2   EUCTR2009-016003-26-GB   United Kingdom
Myfortic 360MG tablets
   UHB NHS Foundation Trust
      2010   Phase 2   EUCTR2009-016003-26-GB   United Kingdom
Myfortic plus LOW-dose steroid
   The University of Hong Kong
      2010   Phase 4   NCT01185197   China
Narsoplimab
   Omeros Corporation
      2016   Phase 2   NCT02682407   Hong Kong;United States
Neoral
   Hopital Erasme
      2006   Phase 4   EUCTR2005-004469-40-BE   Belgium
      2006   Phase 4   EUCTR2005-004460-22-BE   Belgium
None YET
   Boehringer Ingelheim España S.A.
      2022   Phase 2   EUCTR2020-000384-23-ES   Australia;Belgium;France;Germany;Hungary;Ireland;Italy;Spain;United Kingdom;United States
   Boehringer Ingelheim International GmbH
      2022   Phase 2   EUCTR2020-000384-23-IE   Australia;Belgium;China;France;Germany;Ireland;Italy;New Zealand;Spain;United Kingdom;United States
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2022   Phase 2   EUCTR2020-000384-23-DE   Australia;Belgium;China;France;Germany;Hungary;Ireland;Italy;Spain;United Kingdom;United States
   Boehringer Ingelheim SComm
      2022   Phase 2   EUCTR2020-000384-23-BE   Australia;Belgium;China;France;Germany;Ireland;Italy;New Zealand;Spain;United Kingdom;United States
   Boehringer-Ingelheim France
      2022   Phase 2   EUCTR2020-000384-23-FR   Australia;Belgium;France;Germany;Hungary;Ireland;Italy;Spain;United Kingdom;United States
Normal saline
   Bristol-Myers Squibb
      2016   Phase 2   NCT02592798   United States
Obinutuzumab
   Hoffmann-La Roche
      2021   Phase 3   NCT04629248   Argentina;Brazil;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
   Mario Negri Institute for Pharmacological Research
      2022   Phase 2   NCT05050214   Italy
   Mayo Clinic
      2021   Phase 2   NCT04983888   United States
   The Second Hospital of Shanxi Medical University
      2024   -   ChiCTR2400082133   China
   The Second People's Hospital of Shenzhen
      2024   -   ChiCTR2400083188   China
   The University of Queensland
      2024   Phase 3   NCT06120673   Australia
Obinutuzumab injection
   Qianfoshan Hospital
      2023   -   NCT05845762   -
Obinutuzumab/ GA101
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2020-003233-38-IT   Argentina;Brazil;Canada;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
   F.Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-003233-38-PL   Argentina;Brazil;Canada;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
      2021   Phase 3   EUCTR2020-003233-38-FR   Argentina;Brazil;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
Obitunuzumab
   IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
      2021   Phase 2   EUCTR2021-004864-81-IT   Italy
Omnipaque
   IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
      2021   Phase 2   EUCTR2021-004864-81-IT   Italy
OMS721
   Omeros Corporation
      2016   Phase 2   NCT02682407   Hong Kong;United States
Oral cyclosporine
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2010   Phase 2   NCT00977977   United States
Oral prednisolone and cyclophosphamide
   The University of Queensland
      2024   Phase 3   NCT06120673   Australia
Orencia
   Bristol-Myers Squibb Company
      -   Phase 2   EUCTR2015-005450-36-Outside-EU/EEA   United States
OVER-encapsulated 75 MG irbesartan tablets
   Retrophin, Inc.
      2018   Phase 3   EUCTR2016-005141-23-HU   Australia;Belgium;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Italy;Korea, Republic of;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2016-005141-23-ES   Australia;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Korea, Republic of;Poland;South Africa;Spain;Taiwan;United Kingdom;United States
OVER-encapsulated irbesartan
   RETROPHIN, INC
      2018   Phase 3   EUCTR2016-005141-23-IT   Australia;Belgium;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Korea, Republic of;New Zealand;Poland;Portugal;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
   Travere Therapeutics Inc.
      2019   Phase 3   EUCTR2016-005141-23-SE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2016-005141-23-PT   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2016-005141-23-DE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2016-005141-23-BE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2016-005141-23-DK   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2016-005141-23-CZ   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
OVER-encapsulated irbesartan tablets
   Travere Therapeutics Inc.
      2019   Phase 3   EUCTR2016-005141-23-HR   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2016-005141-23-EE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
   Travere Therapeutics, Inc.
      2018   Phase 3   EUCTR2016-005141-23-PL   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
Pegcetacoplan
   APELLIS PHARMACEUTCIALS, INC.
      2022   Phase 3   EUCTR2020-003767-25-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States
      2021   Phase 2   EUCTR2020-002637-15-IT   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
   Apellis Pharmaceuticals, Inc.
      2023   Phase 3   NCT05809531   Argentina;Australia;Belgium;Brazil;Czechia;France;Israel;Italy;Japan;Korea, Republic of;Netherlands;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003767-25-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003767-25-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003767-25-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003767-25-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003767-25-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003767-25-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-003767-25-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
      2021   Phase 3   NCT05067127   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
      2021   -   NCT04729062   United States
      2021   Phase 2   NCT04572854   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2021   Phase 2   EUCTR2020-002637-15-NL   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2021   Phase 2   EUCTR2020-002637-15-FR   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2021   Phase 2   EUCTR2020-002637-15-AT   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      2020   Phase 2   EUCTR2020-002637-15-GB   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2022-002833-33-FR   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2022-002833-33-CZ   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;United Kingdom;United States
      -   Phase 3   EUCTR2020-003767-25-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;Finland;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Peru;Poland;Spain;Switzerland;Ukraine;United Kingdom;United States
   Mizuno Masashi
      2023   Phase 3   JPRN-jRCT2041230022   Argentina;Austrarlia;Austria;Belgium;Brazil;Canada;Czech Republic;France;Germany;Israel;Italy;Japan;Korea;Netherland;Poland;Spain;Switzeland;UK;US
Peginterferon ALFA-2A 180 MCG/ML injectable solution
   Centre Hospitalier Universitaire de Nice
      2023   Phase 2   NCT05941845   France
Pentoxifylline
   National Taiwan University Hospital
      2006   Phase 3   NCT00354731   Taiwan
Perindopril
   Nephrology Division, First Hospital Affiliated to Army Medical University
      2019   Phase 4   ChiCTR1900021757   China
PF-06730512
   PFIZER INC
      2020   Phase 2   EUCTR2019-003607-35-IT   Canada;Czech Republic;Czechia;France;Germany;Italy;Japan;Poland;Romania;Slovakia;Spain;United Kingdom;United States
   Pfizer
      2018   Phase 2   NCT03448692   Canada;Czechia;France;Germany;Italy;Japan;Mexico;Poland;Slovakia;Spain;United Kingdom;United States
   Pfizer Inc.
      2020   Phase 2   EUCTR2019-003607-35-SK   Canada;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Poland;Slovakia;Spain;Thailand;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003607-35-PL   Canada;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Poland;Slovakia;Spain;Thailand;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003607-35-DE   Canada;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Poland;Slovakia;Spain;Thailand;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003607-35-CZ   Canada;Czech Republic;Czechia;France;Germany;Italy;Japan;Poland;Romania;Slovakia;Spain;Thailand;United Kingdom;United States
Pirfenidone
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      1999   Phase 2   NCT00001959   United States
Plasma exchange
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2000   Phase 1/Phase 2   NCT00007475   United States
Plasmapheresis
   University of Minnesota
      2019   Early Phase 1   NCT03763643   United States
Pneumococcal polysaccharide serotype 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F
   APELLIS PHARMACEUTCIALS, INC.
      2021   Phase 2   EUCTR2020-002637-15-IT   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
Pneumococcal polysaccharide serotype 11 2.2 µG
   APELLIS PHARMACEUTCIALS, INC.
      2021   Phase 2   EUCTR2020-002637-15-IT   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
Pneumococcal polysaccharide vaccine solution FOR injection IN A vial
   APELLIS PHARMACEUTCIALS, INC.
      2021   Phase 2   EUCTR2020-002637-15-IT   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
Ponticelli regimen
   Beijing Friendship Hospital
      2020   Phase 4   NCT04424862   China
Povetacicept
   Alpine Immune Sciences, Inc.
      2023   Phase 1/Phase 2   NCT05732402   Australia;Austria;Korea, Republic of;Norway;Puerto Rico;Spain;United Kingdom;United States
Prednisolone
   Astellas Pharma Korea, Inc.
      2012   Phase 4   NCT01763580   Korea, Republic of
      -   -   EUCTR2015-001039-18-Outside-EU/EEA   Korea, Republic of
   Children's Hospital Affiliated to Fudan UniversityNanjing Children's Hospital
      2010   -   ChiCTR-TRC-10000871   China
   Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan
      2007   -   JPRN-UMIN000000621   Japan
   Japanese Study Group of Renal Disease in Children(JSRDC)
      2006   -   JPRN-C000000158   Japan
      2001   -   JPRN-C000000379   Japan
   Shanghai Jiaotong University Affiliated Ruijin Hospital
      2008   -   ChiCTR-TRC-10001024   China
   The University of Hong Kong
      2010   Phase 4   NCT01185197   China
   UHB NHS Foundation Trust
      2010   Phase 2   EUCTR2009-016003-26-GB   United Kingdom
Prednisolone acetate
   Fundacion Renal Iñigo Alvarez Toledo
      2015   -   EUCTR2013-000226-55-NL   Netherlands;Spain
Prednisolone and chlorambucil
   Hospital Authority, Hong Kong
      2003   Phase 3   NCT00404833   China
Prednisolone and mycophenolate mofetil
   Hospital Authority, Hong Kong
      2003   Phase 3   NCT00404833   China
Prednisona
   Grupo Catalán de Estudio de enfermedades glomerulares. Sociedad Catalana de nefrología.
      2008   -   EUCTR2007-005410-39-ES   Spain
Prednisone
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
      2019   Phase 2   EUCTR2018-003437-15-FR   France
   Affiliated Hospital of Guangdong Medical University
      2020   Phase 0   ChiCTR2100041655   China
   Assistance Publique - Hôpitaux de Paris
      2020   Phase 2   NCT03970577   France
      2009   Phase 3   NCT01197040   France
   Astellas Pharma Global Development, Inc.
      2017   Phase 2   NCT02921789   Canada;United States
   Department of Nephrology, The First Affiliated Hospital of Bengbu Medical College
      2017   Phase 4   ChiCTR1900027627   China
   Institute of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
      2006   -   ChiCTR-OPN-17012789   China
   Jianhua Zhou
      2023   Phase 4   NCT05772871   China
   Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University
      2011   -   ChiCTR-TRC-11001454   China
   Longhua Hospital Affiliated to Shanghai University of TCM
      2008   Phase 1 study   ChiCTR-TRC-08000098   China
   Peking Union Medical College Hospital
      2021   Phase 3   NCT04745728   China
   Radboud University
      2018   Phase 3   NCT03298698   Netherlands
   Renmin Hospital of Wuhan University
      2024   Phase 2   NCT06614985   China
   Shanghai Children's Hospital
      2020   Phase 0   ChiCTR2000037014   China
   Shanghai Jiaotong University Affiliated Ruijin Hospital
      2008   -   ChiCTR-TRC-10001024   China
   The First Affiliated Hospital of Bengbu Medical College
      2020   Phase 4   ChiCTR2000033766   China
   The First Affiliated Hospital, College of Medicine, Zhejiang University
      2024   Phase 4   ChiCTR2400081948   China
   Treatment center of kidney disease, 281th hospital of PLA
      2009   Phase 1 study   ChiCTR-TQR-12002602   China
   Wenhu Liu
      2018   -   NCT03466801   China
   Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
      2018   -   NCT03864250   China
      2018   -   NCT03549663   China
   the First Affiliated Hospital of Third Military Medical University
      2018   -   ChiCTR1800014719   China
Prednisone 0,5 MG/KG orally ON alternate days
   Radboud University
      2002   Phase 2/Phase 3   NCT00135967   Netherlands
Prednisone acetate
   The Second Affiliated Hospital of Nanchang University
      2023   -   ChiCTR2300076737   China
Prednisone, ciclosporin and mycophenolate mofetil
   Beijing Friendship Hospital
      2020   Phase 4   NCT04424862   China
Prednisone, FK506, MMF
   Xi’an Jiaotong University College of Medicine
      2009   -   NCT00956059   China
Prednisone,methylprednisone and cyclophosphamide
   Beijing Friendship Hospital
      2023   -   NCT06245707   China
Prevenar 13 - 0.5 ML sospensione iniettabile - USO intramuscolare - flaconcino monodose (0,5 ML vetro tipo I) - 1 flaconcino monodose
   ACHILLION PHARMACEUTICALS, INC.
      2018   Phase 2   EUCTR2017-002674-39-IT   Australia;Belgium;Italy;Netherlands;United States
Prevenar 13 suspension FOR injection
   APELLIS PHARMACEUTCIALS, INC.
      2021   Phase 2   EUCTR2020-002637-15-IT   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
Prograf
   Astellas Pharma Korea, Inc.
      -   -   EUCTR2015-001039-18-Outside-EU/EEA   Korea, Republic of
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2020-003233-38-IT   Argentina;Brazil;Canada;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
R3r01
   River 3 Renal Corp.
      2022   Phase 2   NCT05267262   Belgium;France;Germany;Netherlands;United Kingdom;United States
   River 3 Renal, Corporation
      2022   Phase 2   EUCTR2021-004192-13-NL   Belgium;France;Germany;Netherlands;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004192-13-BE   Belgium;France;Germany;Netherlands;United Kingdom;United States
      -   Phase 2   EUCTR2021-004192-13-FR   Belgium;France;Germany;Netherlands;United Kingdom;United States
RE-021
   RETROPHIN, INC
      2018   Phase 3   EUCTR2016-005141-23-IT   Australia;Belgium;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Korea, Republic of;New Zealand;Poland;Portugal;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
   Retrophin, Inc
      2015   Phase 2   EUCTR2014-002358-38-BE   Belgium;Czech Republic;Italy
      2014   Phase 2   EUCTR2014-002358-38-IT   Belgium;Czech Republic;Italy
   Retrophin, Inc.
      2018   Phase 3   EUCTR2016-005141-23-HU   Australia;Belgium;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Italy;Korea, Republic of;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2016-005141-23-GB   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2016-005141-23-ES   Australia;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Korea, Republic of;Poland;South Africa;Spain;Taiwan;United Kingdom;United States
      2013   -   NCT01622738   United States
   TRAVERE THERAPEUTICS, INC
      2022   Phase 2   EUCTR2021-000621-27-IT   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
   Travere Therapeutics Inc.
      2019   Phase 3   EUCTR2016-005141-23-HR   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2016-005141-23-EE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
   Travere Therapeutics, Inc.
      2022   Phase 2   EUCTR2021-000621-27-SE   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2022   Phase 2   EUCTR2021-000621-27-NL   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2022   Phase 2   EUCTR2021-000621-27-FR   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2021   Phase 2   EUCTR2021-000621-27-ES   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2016-005141-23-PL   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
      2015   Phase 2   EUCTR2014-002358-38-CZ   Belgium;Czech Republic;Czechia;Italy
      2014   Phase 2   NCT01613118   Belgium;Czech Republic;Czechia;Italy;United States
      -   Phase 2   EUCTR2021-000621-27-PL   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      -   Phase 2   EUCTR2021-000621-27-DE   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
Repagermanium
   Dimerix Bioscience Pty Ltd
      2022   Phase 3   EUCTR2021-004174-64-FR   Argentina;Australia;Brazil;Denmark;France;Hong Kong;Korea, Republic of;New Zealand;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-004174-64-ES   Argentina;Australia;Brazil;Denmark;France;Hong Kong;Korea, Republic of;New Zealand;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-004174-64-DK   Argentina;Australia;Brazil;Denmark;France;Hong Kong;New Zealand;Spain;Taiwan;United Kingdom;United States
Repository corticotropin injection
   Mallinckrodt
      2011   Phase 4   NCT01386554   Canada;Chile;Mexico;Turkey;United States
Rilzabrutinib
   Sanofi
      2024   Phase 2   NCT06500702   Argentina;Australia;Brazil;Canada;Chile;China;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Rituximab
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
      2019   Phase 2   EUCTR2018-003437-15-FR   France
   Alice Bertaina
      2023   Phase 1/Phase 2   NCT05508009   United States
   Assistance Publique - Hôpitaux de Paris
      2020   Phase 2   NCT03970577   France
      2012   Phase 3   NCT01508468   France
   Assiut University
      2017   Phase 3   NCT03180723   -
   Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
      2012   Phase 3   NCT03018535   Italy
   Beijing Friendship Hospital
      2023   -   NCT06245707   China
      2022   -   NCT05782933   China
   Cambridge University Hospitals NHS Foundation Trust
      2019   Phase 3   EUCTR2018-004611-50-GB   United Kingdom
   Centre Hospitalier Universitaire de Nice
      2020   Phase 2   NCT03804359   France
   Cerium Pharmaceuticals, Inc.
      2023   Phase 3   NCT05696613   Canada;India;United States
   Department of Medicine, Kidney Center, Tokyo Women's Medical University
      2011   Phase 3   JPRN-UMIN000005231   Japan
   Department of Nephrology, Army Medical Center of PLA
      2022   Phase 4   ChiCTR2200065822   China
   Fundacion Renal Iñigo Alvarez Toledo
      2015   -   EUCTR2013-000226-55-NL   Netherlands;Spain
   George W. Burke
      2012   Phase 3   NCT01164098   United States
   Hospital Universitario 12 de Octubre
      2014   Phase 3   NCT01955187   Spain
   IST. DI RICERCHE FARMACOLOG. M. NEGRI
      2009   Phase 3   EUCTR2008-006750-17-IT   Italy
   Mario Negri Institute for Pharmacological Research
      2009   Phase 3   NCT00981838   Italy
   Mayo Clinic
      2013   Phase 2   NCT01573533   Canada;United States
      2011   Phase 2/Phase 3   NCT01180036   Canada;United States
      2006   Phase 0   NCT00405340   United States
      2005   Phase 1   NCT00275613   United States
      2004   Phase 2/Phase 3   NCT00425217   United States
   National Institute of Allergy and Infectious Diseases (NIAID)
      2020   Phase 2   NCT03949855   Canada;United States
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2008   Phase 2   NCT00550342   United States
   Novartis Farmacéutica, S.A.
      2019   Phase 2   EUCTR2019-001734-34-ES   Argentina;Czech Republic;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;United Kingdom;United States
   Novartis Pharma AG
      2020   Phase 2   EUCTR2019-001734-34-NL   Argentina;China;Czechia;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2019-001734-34-GB   Argentina;Czech Republic;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2019-001734-34-FR   Argentina;Czech Republic;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2019-001734-34-DE   Argentina;China;Czech Republic;Czechia;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States
   Novartis Pharmaceuticals
      2019   Phase 2   NCT04154787   Argentina;China;Czechia;France;Germany;India;Netherlands;Singapore;Spain;Taiwan;United Kingdom;United States
   Peking Union Medical College Hospital
      2021   Phase 3   NCT04745728   China
      2021   Phase 3   NCT04743739   China
   Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
      2020   Phase 4   ChiCTR2000033540   China
   Peking University Third Hospital
      2022   -   ChiCTR2200057381   China
   Qianfoshan Hospital
      2023   -   NCT05667909   -
   Radboud University
      2018   Phase 3   NCT03298698   Netherlands
   Shanghai Children's Hospital
      2022   Phase 0   ChiCTR2200057174   China
   Shanghai Children’s Hospital
      2025   Phase 0   ChiCTR2500101933   China
   Shanghai Dongfang Hospital
      2021   Phase 0   ChiCTR2100049205   China
   Shoichi Maruyama
      2023   Phase 3   JPRN-jRCT2041230037   -
   Shoichi Maruyama MD PhD
      2023   Phase 3   NCT05914155   Japan
   The First Affiliated Hospital of Shandong First Medical University&Shandong Provincial Qianfoshan Hospital
      2021   -   ChiCTR2100050205   China
   The First Affiliated Hospital, Sun Yat-Sen University
      2020   Phase 4   ChiCTR2000040799   China
   The Second Affiliated Hospital of Nanchang University
      2023   -   ChiCTR2300076737   China
   Tokyo Metropolitan Geriatric Hospital
      2016   -   JPRN-UMIN000022150   Japan
   University of Minnesota
      2019   Early Phase 1   NCT03763643   United States
   Xijing Hospital
      2022   Phase 0   ChiCTR2200064268   China
   Xinqiao Hospital
      2020   Phase 4   ChiCTR2000032523   China
   Zhujiang Hospital
      2016   Phase 2   NCT02966717   China
Rituximab combined with corticosteroids
   First Affiliated Hospital, Sun Yat-Sen University
      2024   Phase 4   NCT05514015   China
Rituximab combined with tacrolimus induction + rituximab maintenance
   RenJi Hospital
      2022   -   NCT05532111   -
   Renji Hospital Affiliated to Shanghai jiao tong university school of medicine
      2022   -   ChiCTR2200063389   China
Rituximab combined with tacrolimus induction + tacrolimus maintenance
   RenJi Hospital
      2022   -   NCT05532111   -
   Renji Hospital Affiliated to Shanghai jiao tong university school of medicine
      2022   -   ChiCTR2200063389   China
Rituximab infusion
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2010   Phase 2   NCT00977977   United States
Rituximab injection
   Centre Hospitalier Universitaire de Nice
      2024   Phase 3   NCT06341205   -
Rituximab, cyclophosphamide, and corticosteroids
   St. Petersburg State Pavlov Medical University
      2018   -   NCT05679336   Russian Federation
RO0485337
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2020-003233-38-IT   Argentina;Brazil;Canada;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
   F.Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-003233-38-PL   Argentina;Brazil;Canada;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
      2021   Phase 3   EUCTR2020-003233-38-FR   Argentina;Brazil;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
RO5072759
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2020-003233-38-IT   Argentina;Brazil;Canada;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
   F.Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-003233-38-PL   Argentina;Brazil;Canada;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
      2021   Phase 3   EUCTR2020-003233-38-FR   Argentina;Brazil;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
   IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
      2021   Phase 2   EUCTR2021-004864-81-IT   Italy
Rosiglitazone
   North Shore Long Island Jewish Health System
      2005   Phase 1   NCT00193648   United States
RTX
   Ruijin Hospital, affiliated to Shanghai Jiaotong University, School of medicine
      2016   Phase 4   ChiCTR-IPR-16008527   China
Sacubitril
   China-Japan Friendship Hospital
      2021   Phase 4   ChiCTR2100050967   China
Sanqi
   Guangdong Provincial Hospital of Traditional Chinese Medicine
      2022   -   ChiCTR2200061953   China
SAR442970
   Sanofi
      2024   Phase 2   NCT06500702   Argentina;Australia;Brazil;Canada;Chile;China;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Serum albumin
   The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese
      2024   -   ChiCTR2400091949   China
   Yuebei People’s Hospital
      2022   Phase 0   ChiCTR2200058162   China
SGB-9768
   Suzhou Sanegene Bio Inc.
      2025   Phase 2   NCT06786338   China
SHR1459 high dose
   Reistone Biopharma Company Limited
      2021   Phase 2   NCT05136456   China
SHR1459 LOW dose
   Reistone Biopharma Company Limited
      2021   Phase 2   NCT05136456   China
Sinomenine
   Macau University of Science and Technology
      2021   Phase 4   ChiCTR2100047996   China
Sirolimus
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2002   Phase 2   NCT00050713   United States
      2002   Phase 2   NCT00040508   United States
   Renal Division, Peking University First Hospital
      2017   -   ChiCTR-INR-17012212   China
SNP-acth (1-39) GEL
   Cerium Pharmaceuticals, Inc.
      2023   Phase 3   NCT05696613   Canada;India;United States
Soliris
   IRCCS- Mario Negri Institute
      2014   Phase 2   EUCTR2013-003826-10-IT   Italy
Solondo
   Astellas Pharma Korea, Inc.
      -   -   EUCTR2015-001039-18-Outside-EU/EEA   Korea, Republic of
Sparsentan
   RETROPHIN, INC
      2018   Phase 3   EUCTR2016-005141-23-IT   Australia;Belgium;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Korea, Republic of;New Zealand;Poland;Portugal;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
   Retrophin, Inc
      2015   Phase 2   EUCTR2014-002358-38-BE   Belgium;Czech Republic;Italy
      2014   Phase 2   EUCTR2014-002358-38-IT   Belgium;Czech Republic;Italy
   Retrophin, Inc.
      2018   Phase 3   EUCTR2016-005141-23-HU   Australia;Belgium;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Italy;Korea, Republic of;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2016-005141-23-ES   Australia;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Korea, Republic of;Poland;South Africa;Spain;Taiwan;United Kingdom;United States
   TRAVERE THERAPEUTICS, INC
      2022   Phase 2   EUCTR2021-000621-27-IT   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
   Travere Therapeutics Inc.
      2019   Phase 3   EUCTR2016-005141-23-SE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2016-005141-23-PT   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2016-005141-23-DE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2016-005141-23-BE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2016-005141-23-DK   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2016-005141-23-CZ   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
   Travere Therapeutics, Inc.
      2022   Phase 2   EUCTR2021-000621-27-SE   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2022   Phase 2   EUCTR2021-000621-27-NL   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2022   Phase 2   EUCTR2021-000621-27-FR   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2021   Phase 2   NCT05003986   Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2021   Phase 2   EUCTR2021-000621-27-ES   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   NCT03493685   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
      2015   Phase 2   EUCTR2014-002358-38-CZ   Belgium;Czech Republic;Czechia;Italy
      2014   Phase 2   NCT01613118   Belgium;Czech Republic;Czechia;Italy;United States
      -   Phase 2   EUCTR2021-000621-27-PL   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      -   Phase 2   EUCTR2021-000621-27-DE   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
Sparsentan/OVER-encapsulated sparsentan tablet
   Travere Therapeutics, Inc.
      2018   Phase 3   EUCTR2016-005141-23-PL   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
Sparsentan/OVER-encapsulated sparsentan tablets
   Retrophin, Inc.
      2018   Phase 3   EUCTR2016-005141-23-GB   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
   Travere Therapeutics Inc.
      2019   Phase 3   EUCTR2016-005141-23-HR   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2016-005141-23-EE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
Standard OF care IST
   Biogen
      2025   Phase 3   NCT06962800   United States
Sulfate
   Nephrology Division, First Hospital Affiliated to Army Medical University
      2019   Phase 4   ChiCTR1900021757   China
Synacthen depot 1MG
   Radboud University Nijmegen Medical Center
      2008   -   EUCTR2008-001647-19-NL   Netherlands
Tacrolimus
   Astellas Pharma Korea, Inc.
      2012   Phase 4   NCT01763580   Korea, Republic of
      -   -   EUCTR2015-001039-18-Outside-EU/EEA   Korea, Republic of
   Baoji Central Hospital
      2016   -   ChiCTR-IPR-16008344   China
   BeiGene
      2023   Phase 2/Phase 3   NCT05707377   Argentina;Brazil;Canada;China;Czechia;Italy;Mexico;Poland;Spain;Turkey;United Kingdom;United States
   Biogen
      2025   Phase 3   NCT06962800   United States
   Children's Hospital, Zhejiang University School of Medicine
      2019   Phase 4   ChiCTR1900022943   China
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2020-003233-38-IT   Argentina;Brazil;Canada;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
   F.Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-003233-38-PL   Argentina;Brazil;Canada;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
      2021   Phase 3   EUCTR2020-003233-38-FR   Argentina;Brazil;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
   Fundacion Renal Iñigo Alvarez Toledo
      2015   -   EUCTR2013-000226-55-NL   Netherlands;Spain
   Grupo Catalán de Estudio de enfermedades glomerulares. Sociedad Catalana de nefrología.
      2008   -   EUCTR2007-005410-39-ES   Spain
   Hoffmann-La Roche
      2021   Phase 3   NCT04629248   Argentina;Brazil;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
   Hospital Universitario 12 de Octubre
      2014   Phase 3   NCT01955187   Spain
   Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University
      2011   -   ChiCTR-TRC-11001454   China
   Nanjing University School of Medicine
      2006   -   NCT00302536   China
      2006   -   NCT00302523   China
   People’s Hospital of Songzi
      2022   -   ChiCTR2200058661   China
   Qianfoshan Hospital
      2023   -   NCT05667922   -
   Second Hospital of Jilin University
      2004   -   ChiCTR-TRC-09000539   China
   Seoul National University Hospital
      2010   Phase 4   NCT01162005   Korea, Republic of
   Shenzhen Second People's Hospital
      2020   Phase 4   ChiCTR2000032422   Chiina
   Sichuan Provincial People's Hospital
      2018   -   ChiCTR1800016140   China
   Southwest Hospital, the First Affiliated Hospital of Army Medical University
      2020   Phase 4   ChiCTR2000031003   China
   The First Affiliated Hospital of Bengbu Medical College
      2020   Phase 4   ChiCTR2000033766   China
   The First Affiliated Hospital of Shandong First Medical University&Shandong Provincial Qianfoshan Hospital
      2021   -   ChiCTR2100050205   China
   The First Affiliated Hospital, College of Medicine, Zhejiang University
      2024   Phase 4   ChiCTR2400081948   China
      2022   Phase 4   ChiCTR2200056304   China
   The Second Affiliated Hospital of Nanchang University
      2023   -   ChiCTR2300076737   China
   The Second Affiliated Hospital of Xi'an Jiaotong University
      2021   -   ChiCTR2100048518   China
   The Seventh Affiliated Hospital of Sun Yat sen University
      2023   Phase 4   ChiCTR2200067000   China
   Xijing Hospital
      2022   Phase 0   ChiCTR2200064268   China
   Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
      2018   -   NCT03864250   China
      2018   -   NCT03549663   China
   Xinqiao Hospital
      2020   Phase 4   ChiCTR2000032523   China
   the First Affiliated Hospital of Third Military Medical University
      2018   -   ChiCTR1800014719   China
Tacrolimus capsules
   Astellas Pharma Global Development, Inc.
      2017   Phase 2   NCT02921789   Canada;United States
Tacrolimus combined with prednisone
   Peking University
      2004   Phase 2/Phase 3   NCT00362531   -
Tacrolimus FOR THE treatment OF IMN
   Qianfoshan Hospital
      2023   -   NCT05797038   -
Telitacicept
   Chinese PLA General Hospital
      2023   Phase 0   ChiCTR2300077036   China
   Qilu Hospital of Shandong University
      2022   Phase 4   ChiCTR2200055179   China
   Renmin Hospital of Wuhan University
      2024   Phase 2   NCT06614985   China
Tetracosactide hexacetaat
   Radboud University
      2008   Phase 2   NCT00694863   Netherlands
Tetract-HIB - 1 siringa precaricata 0.5 ML
   ACHILLION PHARMACEUTICALS, INC.
      2018   Phase 2   EUCTR2017-002674-39-IT   Australia;Belgium;Italy;Netherlands;United States
THE 0.5 ML dose OF vaccine contains 25 micrograms OF each OF THE following 23 pneumococcal polysaccharide
   APELLIS PHARMACEUTCIALS, INC.
      2021   Phase 2   EUCTR2020-002637-15-IT   Argentina;Australia;Austria;Brazil;France;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States
THE comprehensive treatment regimen OF traditional chinese medicine
   Shanghai University of Traditional Chinese Medicine
      2010   -   NCT01799460   China
THE immunosuppressive agents
   Shanghai University of Traditional Chinese Medicine
      2010   -   NCT01799460   China
Total body irradiation
   Alice Bertaina
      2023   Phase 1/Phase 2   NCT05508009   United States
Tripterygium wilfordii
   Department of Nephrology, Sichuan Provincial People's Hospital
      2021   -   ChiCTR2100048382   China
   Nanjing University School of Medicine
      2009   -   NCT00801463   China
   Shanxi Hospital of Traditional Chinese Medicine
      2022   Phase 0   ChiCTR2200062685   China
   Zhi-Hong Liu, M.D.
      2010   -   NCT01161459   China
TRU-015
   Wyeth is now a wholly owned subsidiary of Pfizer
      2007   Phase 1   NCT00479622   United States
Truxima
   CHU de Nice
      2019   Phase 2   EUCTR2018-002476-40-FR   France
Truximab
   CHU de Nice
      2019   Phase 2   EUCTR2018-002476-40-FR   France
Urbason*IM EV 1F 250MG+1F 5ML
   AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
      2012   -   EUCTR2011-006115-59-IT   Italy
Valproic acid
   Universitair Ziekenhuis Brussel
      2016   Phase 2/Phase 3   NCT02896270   Belgium
Valsartan
   China-Japan Friendship Hospital
      2021   Phase 4   ChiCTR2100050967   China
   Columbia University
      2009   Phase 4   NCT01129557   United States
   Shijiazhuang Nephropathy Hospital
      2017   -   ChiCTR-INR-17012070   China
   The People's Hospital of Guangxi Zhuang Autonomous Region
      2019   -   ChiCTR1800020241   China
VB119
   Tenet Medicines
      2022   Phase 2   NCT05441826   United States
      2021   Phase 1/Phase 2   NCT04652570   Mexico;United Kingdom;United States
VIS171
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2025   Phase 1   NCT06799520   Moldova, Republic of
Vitamin D
   The People's Hospital of Guangxi Zhuang Autonomous Region
      2019   -   ChiCTR1800020241   China
Voclosporin
   Aurinia Pharmaceuticals Inc.
      2018   Phase 2   NCT03598036   Dominican Republic;United States
VX-147
   Vertex Pharmaceuticals Incorporated
      2023   Phase 1   NCT05955872   United States
      2020   Phase 2   NCT04340362   France;Puerto Rico;United Kingdom;United States
      2020   Phase 2   EUCTR2020-000185-42-GB   France;United Kingdom;United States
      2020   Phase 2   EUCTR2020-000185-42-FR   France;United Kingdom;United States
VX147
   Vertex Pharmaceuticals Incorporated
      2020   Phase 2   EUCTR2020-000185-42-GB   France;United Kingdom;United States
      2020   Phase 2   EUCTR2020-000185-42-FR   France;United Kingdom;United States
WAL0921
   Walden Biosciences
      2024   Phase 2   NCT06466135   Australia;United Kingdom;United States
YK012
   Excyte Biopharma Ltd
      2025   Phase 1   NCT06982729   China
Zanubrutinib
   BeiGene
      2023   Phase 2/Phase 3   NCT05707377   Argentina;Brazil;Canada;China;Czechia;Italy;Mexico;Poland;Spain;Turkey;United Kingdom;United States
Zestril
   Hopital Erasme
      2006   Phase 4   EUCTR2005-004469-40-BE   Belgium
      2006   Phase 4   EUCTR2005-004460-22-BE   Belgium
Zuberitamab 1000MG
   BioRay Pharmaceutical Co., Ltd.
      2024   Phase 2   NCT06642909   China
Zuberitamab 600MG
   BioRay Pharmaceutical Co., Ltd.
      2024   Phase 2   NCT06642909   China